Home » Archive by Category


West Coast Bio Roundup: Illumina, 10X Genomics, Juno, and More

January 18, 2016 – 7:33 am

[Corrected 1/19/16, 10:10 am. See below.] Last week’s annual J.P. Morgan Healthcare Conference put the biotech industry’s biggest event on display, as some 9,000 life sciences executives and…

[[Click headline to continue reading.]]

Grail’s Discount, Pfizergan & Pricing Plans: Notes from the JPM Vortex

January 15, 2016 – 9:03 am

[Editor’s note: Deputy Biotechnology Editor Ben Fidler co-wrote this story] The week of the annual J.P. Morgan Healthcare Conference in San Francisco kicked off with a rousing,…

[[Click headline to continue reading.]]

As Feud Rages, UCSD Names New Director to Lead Alzheimer’s Study

January 14, 2016 – 3:34 pm

UC San Diego today named Howard Feldman, a Canadian neurologist who specializes in dementia, as director of a nationwide Alzheimer’s disease research program riven in a bitter feud between two of the…

[[Click headline to continue reading.]]

Frazier Enlists Three Laguna Pharma Execs to Scout for New Drugs

January 11, 2016 – 10:01 pm

Like a phoenix rising from the shutdown of San Diego’s Laguna Pharmaceuticals, former Laguna CEO Bob Baltera and two other ex-Laguna executives are now roosting under the wing of Menlo Park, CA-based…

[[Click headline to continue reading.]]

Illumina Forms Grail in Quest for Ultimate Cancer Diagnostic

January 10, 2016 – 8:24 pm

Illumina (NASDAQ: ILMN), the San Diego-based pioneer in gene-sequencing technology, says it has formed a new company called Grail to advance the sensitivity of technology already being used to detect…

[[Click headline to continue reading.]]

West Coast Bio Roundup: Big Waves, Big Cash & a Deep Pre-JPM16 Breath

January 8, 2016 – 3:50 pm

I’d say this week was the calm before the J.P. Morgan storm, except that we on the West Coast have had plenty of storms this week. Perhaps not tornadoes, but weather big enough to churn up 50…

[[Click headline to continue reading.]]

With $100M, Guardant Health to Expand Reach of Blood Test for Cancer

January 7, 2016 – 5:30 am

We’ve all heard that dust is at least partly made up of dead skin cells. However true or untrue that may be, living tissue that is growing rapidly, such as a cancerous solid tumor, does indeed shed…

[[Click headline to continue reading.]]

From Ambitions To Markets: Richard Kitney And More Synthetic Bio Views

January 6, 2016 – 4:30 am

Last week, Xconomy ran the first part of my conversation with Richard Kitney, a bioengineering professor at Imperial College London and a pioneer in the field of synthetic biology. We met in his…

[[Click headline to continue reading.]]

NuVasive Buys Skeletal Specialist in First Deal under New CEO

January 5, 2016 – 6:55 pm

San Diego’s NuVasive (NASDAQ: NUVA), a medical device maker that specializes in spinal procedures, said today it is acquiring privately held Ellipse Technologies for $380 million in cash, with an…

[[Click headline to continue reading.]]

Formerly Atterocor, Millendo Changes Name, Strategy—And Nabs $62M

January 5, 2016 – 5:00 am

When a biotech company with one product in development misses its milestones, investors typically don’t throw more money at it. Not so with the newly renamed Millendo Therapeutics. The Ann…

[[Click headline to continue reading.]]